Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06051669
Other study ID # ILT-US-2023-01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 24, 2023
Est. completion date March 2025

Study information

Verified date October 2023
Source New Discovery LLC
Contact Calvin Q Pan, Dr
Phone (718) 888-7728
Email Panc01@nyu.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis and steatosis in adult patients.


Description:

Clinical phase: Phase IV investigator-initiated study Study centers planned: Approximately 4 centers in different regions of the USA Objectives: 1. Primary Objectives To evaluate the consistency of Liver Stiffness Measurement (LSM) and Ultrasound/Controlled Attenuation Parameters (UAP/CAP) between iLivTouch-FT9000 and FibroScan 530 devices. 2. Secondary Objectives 1. To compare the operational features of the two devices, reflected in the success rate of examination and number of effective examinations. 2. To compare LSM obtained from each device with liver stiffness estimated by APRI, FIB-4, and SAFE scores. 3. The number of adverse events, serious events, and percentage of subjects with events will be calculated for AE, SAE, AE of special interest, and AE leading to study withdrawal.


Recruitment information / eligibility

Status Recruiting
Enrollment 418
Est. completion date March 2025
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - a. Adults aged above 18 years old who have at least one indication for TE examination determined by the physicians; - b. Patients who have test results for platelet count, ALT, AST, globulin, HBA1c, and total bilirubin (TBIL) levels within 60 days; - c. Patients who are willing to participate in the clinical study and can sign ICF. Exclusion Criteria: - a. Excessive drinking history within 90 days: For women-140 grams of alcohol per week or more; For men-210 grams of alcohol per week or more; - b. Patients with alanine aminotransferase (ALT) or aspartate aminotransferase AST >100 U/ml (or 2.5 × upper limit of normal (ULN) and/or total bilirubin (TBIL) > 1.8 mg/d (or >1.5 × ULN =1.2 mg/d); - c. Patients with a history or current evidence of decompensated liver cirrhosis; - d. Patients with various space-occupying tumors and cysts in the right liver; - e. Patients with other serious systemically diseases or a history of malignant tumors; - f. Patients with ascites; - g. Patients with a non-healing wound on the right upper abdomen at this moment; - h. Patients with intracavitary implantation of instruments; - i. Pregnant women (urine pregnancy test should be performed for all women with child-bearing potential during screening); - j. Any history of organ transplantation and existing functional grafts (except corneal or hair transplantation); - k. Lack of or limited legal capacity.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
iLivTouch
The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
FibroScan
The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.

Locations

Country Name City State
United States Rush University Chicago Illinois
United States Baylor University Houston Texas
United States NYU Langone New York New York
United States Stanford University Redwood City California

Sponsors (6)

Lead Sponsor Collaborator
New Discovery LLC Baylor University, NYU Langone Health, Rush University, Stanford University, Wuxi Hisky Medical Technology Co Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver Stiffness Measurement (LSM) value from iLivTouch and FibroScan detection Spearman correlation coefficients and 95% confidence interval will be calculated to analyze the correlation of the measurements (LSM) between iLivTouch-FT9000 and FibroScan 530 devices. 6 months
Primary Ultrasound/Controlled Attenuation Parameters (UAP/CAP) from iLivTouch and FibroScan detection Spearman correlation coefficients and 95% confidence interval will be calculated to analyze the correlation of the measurements (UAP/CAP) between iLivTouch-FT9000 and FibroScan 530 devices. 6 months
Secondary To compare the success rate of the iLivTouch and FibroScan The success rate of examination will be obtained from the percentage of patients who are successful in the test. 6 months
Secondary To compare the number of effective examinations of iLivTouch and FibroScan The number of effective examinations will be obtained from the number of attempts to obtain the effective results. 6 months
Secondary Liver stiffness measurement (LSM) and AST to Platelet Ratio Index (APRI) To compare LSM obtained from each device with liver stiffness estimated by APRI.
Two liver fibrosis detection results based on LSM and APRI will be compared. The higher values mean more serious fibrosis.
6 months
Secondary Liver stiffness measurement (LSM) and Fibrosis-4 (FIB-4) Two liver fibrosis detection results based on LSM and FIB-4 will be compared. FIB-4 refers to Age (years), AST Level (U/L), Platelet Count (10^9/L), ALT (U/L), with higher values mean more serious fibrosis. 6 months
Secondary Liver stiffness measurement (LSM) and Steatosis-associated Fibrosis Estimator (SAFE) scores Two liver fibrosis detection results based on LSM and SAFE scores will be compared. The higher values mean more serious fibrosis. 6 months
Secondary Adverse events, serious events The number of adverse events, serious events, and percentage of subjects with events will be calculated for AE, SAE, AE of special interest, and AE leading to study withdrawal. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Completed NCT02565446 - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram N/A
Not yet recruiting NCT01694342 - Telomere Parameters in Patients With Nonalcoholic Fatty Liver N/A
Completed NCT01464801 - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease N/A
Completed NCT01992809 - Omega 3 Supplementation in Fatty Liver Phase 3
Completed NCT00063635 - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Phase 3
Completed NCT00244569 - Development of a Breath Test for Monitoring Patients With Liver Disease Phase 3
Recruiting NCT03972319 - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study Early Phase 1
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT05125757 - Lifestyle Modification in Psoriatic Patients With Fatty Liver N/A
Recruiting NCT05370053 - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology N/A
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting NCT02265276 - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Phase 3
Completed NCT02347007 - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Completed NCT01234714 - Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications N/A